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Abstract 1 
Severe pain is a common and debilitating complication to metastatic bone cancer. Current analgesics 2 
provide insufficient pain relief and often lead to significant adverse effects. In models of cancer-3 
induced bone pain pathological sprouting of sensory fibers at the tumor-bone interface occurs 4 
concomitantly to reactive astrocytosis in the dorsal horn of the spinal cord. We observed that CGRP-5 
fiber sprouting in the bone was associated with an increase in CGRP content in sensory neuron cell 6 
bodies in the dorsal root ganglia (DRG), and increased basal and activity-evoked release of CGRP from 7 
their central terminals in the dorsal horn. Intrathecal administration of a peptide antagonist (α-8 
CGRP8-37) attenuated referred allodynia in the hindpaw ipsilateral to bone cancer. CGRP receptor 9 
components (CLR and RAMP1) were up-regulated in dorsal horn neurons and expressed by reactive 10 
astrocytes. In primary cultures of astrocyte, CGRP incubation led to a concentration-dependent 11 
increase of forskolin-induced cAMP production which was attenuated by pre-treatment with CGRP8-12 
37. Furthermore, CGRP induced ATP release in astrocytes which was inhibited by CGRP8-37. We 13 
suggest that the peripheral increase in CGRP content observed in cancer-induced bone pain is 14 
mirrored by a central increase in the extracellular levels of CGRP. This increase in CGRP may not only 15 
facilitate glutamate-driven neuronal nociceptive signaling, but also act on astrocytic CGRP receptors 16 
and lead to release of ATP.  17 
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Abstract 25 
Severe pain is a common and debilitating complication to metastatic bone cancer. Current analgesics 26 
provide insufficient pain relief and often lead to significant adverse effects. In models of cancer-27 
induced bone pain pathological sprouting of sensory fibers at the tumor-bone interface occurs 28 
concomitantly to reactive astrocytosis in the dorsal horn of the spinal cord. We observed that CGRP-29 
fiber sprouting in the bone was associated with an increase in CGRP content in sensory neuron cell 30 
bodies in the dorsal root ganglia (DRG), and increased basal and activity-evoked release of CGRP from 31 
their central terminals in the dorsal horn. Intrathecal administration of a peptide antagonist (α-32 
CGRP8-37) attenuated referred allodynia in the hindpaw ipsilateral to bone cancer. CGRP receptor 33 
components (CLR and RAMP1) were up-regulated in dorsal horn neurons and expressed by reactive 34 
astrocytes. In primary cultures of astrocyte, CGRP incubation led to a concentration-dependent 35 
increase of forskolin-induced cAMP production which was attenuated by pre-treatment with CGRP8-36 
37. Furthermore, CGRP induced ATP release in astrocytes which was inhibited by CGRP8-37. We 37 
suggest that the peripheral increase in CGRP content observed in cancer-induced bone pain is 38 
mirrored by a central increase in the extracellular levels of CGRP. This increase in CGRP may not only 39 
facilitate glutamate-driven neuronal nociceptive signaling, but also act on astrocytic CGRP receptors 40 
and lead to release of ATP.  41 
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1. Introduction 42 
Breast, prostate and lung cancers are highly metastatic to the bone. A frequent complication in 43 
patients with metastatic disease is cancer-induced bone pain, which starts as intermittent pain that 44 
becomes constant with time. Furthermore, the occurrence of breakthrough pain, either spontaneous 45 
or due to weight-bearing and movement of the metastatic site, results in poor quality of life in 46 
patients [4,27,37]. 47 
Recent pre-clinical studies indicate that skeletal pain in primary and metastatic bone cancer 48 
includes a neuropathic component. Cancer-induced bone pain is associated with an initial tumor-49 
induced nerve injury of distal processes of sensory fibers, but also sprouting and formation of 50 
neuroma-like structures by sensory and sympathetic fibers innervating the tumor-bearing site [3,20]. 51 
The current view is that nerve growth factor (NGF) released by endogenous stromal, immune and 52 
inflammatory cells drives the sensory fiber ectopic sprouting as this is significantly decreased by early 53 
anti-NGF treatment without any effect on either bone destruction or tumor growth [25]. Consistent 54 
with the possibility that nerve fiber sprouting contributes to skeletal pain, pre-emptive and sustained 55 
anti-NGF treatment attenuates cancer-induced pain behavior whereas late and acute treatment after 56 
the appearance of sprouting exerts limited effect [21,26,35]. This suggests that the sprouting of 57 
sensory afferents is critical for the development of cancer-induced bone pain, and it has been 58 
proposed that such pathological reorganization renders fibers highly sensitive to movement of the 59 
tumor-bearing limb and may lead to spontaneous discharge [26].  60 
The bone is mainly innervated by thinly myelinated A-delta sensory fibers and peptidergic C-61 
fibers; the large majority of which express calcitonin gene-related peptide (CGRP)[5]. Accordingly 62 
there is a highly significant cancer-induced sprouting of CGRP expressing fibers that is matched by 63 
higher numbers of CGRP-positive neuronal cell bodies in dorsal root ganglia (DRG) ipsilateral to the 64 
cancer-bearing bone [3,20,29]. Such up-regulation of CGRP in the DRG is the likely product of 65 
increased translation which is promoted by retrogradely transported NGF in TrkA-expressing sensory 66 
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neurons [31]. Current evidence suggests that whilst more CGRP is shuttled to the peripheral 67 
terminals of sensory neurons no changes in CGRP expression can be observed in the dorsal horn 68 
ipsilateral to the cancer-bearing bone [19]. However, the dorsal horn pool of CGRP plays a significant 69 
role in central mechanisms of nociceptive signaling [24]. In particular the occurrence of referred 70 
allodynia, a typical feature of cancer-induced bone pain, suggests the involvement of a state of 71 
central sensitization. 72 
Here we tested the hypothesis that an up-regulation of CGRP in sensory neurons innervating 73 
the bone is mirrored by an increased release of CGRP from their central terminals in the dorsal horn 74 
where CGRP can facilitate neuronal nociceptive signaling in cancer-induced bone pain. Also, as the 75 
induction of bone cancer is associated with reactive astrocytes in the dorsal horn [18,19], we 76 
investigated whether astrocytes express CGRP receptors and respond to CGRP application. 77 
 78 
2. Materials and Methods 79 
2.1. Experimental animals 80 
A total of 77 male C3H/HeN mice (Harlan, Oxfordshire, UK), 5-7 weeks old were used in 81 
experiments. Groups of 5 mice were housed at a 12-hour light/dark cycle in a temperature and 82 
humidity controlled environment. They were provided with wood-chip bedding material and allowed 83 
free access to water and standard diet. All procedures were performed in accordance with the 84 
United Kingdom Home Office regulations and followed the guidelines of the International Association 85 
for the Study of Pain [43]. 86 
  87 
2.2. Cancer cell line  88 
NCTC clone 2472 was obtained from the American Type Culture Collection (CCL-11, ATCC, LGC 89 
Standards, Middlesex, UK). Cells were cultured in NCTC-135 medium (Sigma-Aldrich, Dorset, UK) 90 
supplemented with sodium hydrogen-carbonate and 10% equine serum (Sigma-Aldrich). NCTC 2472 91 
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cells used for induction of bone cancer were all in passage 7-10. Cells were harvested at 92 
approximately 70% conﬂuency with 1 mM EDTA in 0.1 M phosphate buffered saline (D-PBS, Life 93 
Technologies, Paisley, UK), resuspended in Dulbecco's Modified Eagle Medium (D-MEM, Life 94 
Technologies), and kept on ice until inoculation. 95 
 96 
2.3. Mouse model of cancer-induced bone pain 97 
Bone cancer was induced as previously described [32] with a few modiﬁcations. In brief, mice 98 
were anaesthetized with isoflurane (IsoFlo®, 2-3% in 1 L/min oxygen) or a mixture of 99 
Hypnorm/Hypnovel (VetaPharma Ltd. and Roche, s.c., 2.5 mg/ml fluanisone, 0.079 mg/ml fentanyl 100 
citrate, and 1.25 mg/ml midazolam). Post-operative analgesic was provided (Carprieve, Norbrook, 4 101 
mg/kg, s.c.). An incision was made over the right patella and arthrotomy performed to expose the 102 
distal femoral epiphysis. A hole was drilled into the medullary cavity with a 30-gauge needle (BD 103 
Microlance 3, 30G x 0.5”, VWR, Leicestershire, UK) and 10 μl D-MEM containing 100,000 NCTC 2472 104 
cells was inoculated with an insulin syringe (BD Micro-Fine Plus Insulin Syringes, 0.3 ml, 30G x 8 mm, 105 
VWR). The hole was closed with surgical Ethicon bone wax (Harvard Apparatus, Cambridge, UK) and 106 
thoroughly irrigated with sterile saline. The skin was closed with surgical wound clips (Scientific 107 
Laboratory Supplies Ltd, Nottingham, UK). Sham operated control mice underwent the same 108 
operation but were inoculated with D-MEM alone. 109 
  110 
2.4. Behavioral testing 111 
Pain-related behaviors were assessed in mice before inoculation of media or cancer cells and 112 
at various time intervals after inoculation. Mice were randomly assigned to surgery and treatment 113 
groups and the experimenter was blinded to treatments. Tactile allodynia was assessed with a series 114 
of calibrated von Frey monoﬁlaments (0.04 g – 4.0 g, Stoelting Co., Wood Dale, IL). The Dixon up and 115 
down method was used and a 50% paw withdrawal threshold (PWT) calculated as previously 116 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6/30 
 
described [6,11]. Prior to testing, mice were habituated for at least 45 min in test boxes placed upon 117 
an elevated metal grid to allow access to the hindpaw. Monoﬁlaments were applied perpendicular to 118 
the plantar surface of the hindpaw until a slight bend was observed. Each test started with 119 
application of the 0.6 g filament and a response was regarded as positive when a visible reﬂex paw 120 
withdrawal response occurred or the cut-off thresholds of 0.04 g or 4.0 g were reached. Lack of a 121 
response led to application of next higher force, while a positive response led to application of next 122 
lower force. The weight borne on each hind limb was measured with an Incapacitance Tester (Linton 123 
Instruments, Norfolk, UK). Mice were allowed to freely step into the test chamber and encouraged to 124 
rest each hind limb on separate transducer pads. Once the mouse was settled in the correct position 125 
the weight load of each hind limb was recorded. Mice were forced to change position in between 126 
three consecutive measurements by a gentle pull of the tail, and an average weight bearing ratio was 127 
calculated as follows: weight placed on the ipsilateral hind limb divided by weight on ipsilateral + 128 
contralateral hind limbs. This average ratio was used for statistical analysis. Limb use scores were 129 
assigned after examination of the gait of the operated hind limb. Mice were allowed to move freely 130 
in a transparent standard cage (365 mm x 207 mm x 140 mm, polycarbonate, Tecniplast UK, London, 131 
UK) containing wood chip bedding to allow secure foothold. After a 3 min observation period a score 132 
ranging from 4-0 was assigned as follows: 4 = normal gait, 3 = minor limping, 2 = substantial limping, 133 
1 = substantial limping and partial lack of limb use, 0 = total lack of limb use. 134 
  135 
2.5. Ex-vivo release of calcitonin gene-related peptide from dorsal horn slices 136 
Extracellular release of CGRP into the dorsal horn was measured in an ex-vivo dorsal horn slice 137 
preparation with dorsal roots attached. Only cancer-bearing mice exhibiting a limb use score ≤ 3 138 
were selected for release experiments. Lumbar spinal cords were excised in order to obtain 139 
horizontal dorsal horn slices with L3, L4 and L5 dorsal roots attached [8,30]. Slices were mounted in 140 
the central compartment of a three-compartment chamber and continuously superfused at 1 ml/min 141 
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with oxygenated Krebs’ solution (118 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM 142 
NaHCO3, 2.5 mM CaCl2, and 11 mM glucose; 95% O2/5% CO2) supplemented with 0.1% bovine serum 143 
albumin (BSA, Sigma-Aldrich, Dorset, UK) and 2 mg/mL of bacitracin (Sigma-Aldrich) to minimize 144 
peptide degradation. The dorsal roots were placed on two electrodes in the lateral compartments 145 
and immersed in mineral oil to avoid dehydration. The dorsal horn slices were left to equilibrate for 1 146 
hour prior to collection of 8 ml fractions of superfusates from the central compartment into glass 147 
tubes containing acetic acid (0.1 M, Sigma-Aldrich). Three 8 ml fractions were collected to measure 148 
the basal outflow of CGRP, followed by one fraction to measure activity-evoked release of CGRP 149 
during 8 min electrical stimulation of the dorsal roots at C-fiber strength (20 V, 0.5 ms, 10 Hz) to 150 
mimic fibre activity during noxious stimulation. Lastly three fractions were collected to measure the 151 
recovery to basal levels of CGRP. The CGRP content in the collected fractions was quantified using a 152 
peptide enzyme immunoassay (EIA, α-calcitonin gene-related peptide, Peninsula Laboratories, San 153 
Carlos, CA). Briefly the fractions were partially purified and desalted through C18 reverse phase silica 154 
gel cartridges (Waters UK, Hertfordshire, UK). Cartridges were conditioned with acetonitrile and 0.1% 155 
trifluoroacetic acid (TFA). The sample fraction was loaded and a wash performed with 0.1% TFA, 156 
before elution with a mixture of acetonitrile/0.1% TFA (80:20). The eluted samples were dried at 157 
55°C under nitrogen gas. Dried samples were reconstituted in 150 μl assay diluent. 50 μl of CGRP 158 
standards (0.01 – 10.00 ng/ml) and 50 μl of unknown samples were run in duplicate according to the 159 
manufacture instructions. Absorbance of each sample was measured at 450 nm and CGRP content 160 
calculated from the sigmoidal standard curve using nonlinear regression and the paradigm 161 
“log(inhibitor) vs. response - Variable slope” (GraphPad Prism v. 5.01, GraphPad Software Inc., La 162 
Jolla, CA). 163 
 164 
2.6. Drug treatment 165 
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Vehicle (saline) or α-CGRP8-37 (dissolved in saline; Bachem AG, Bubendorf, Switzerland) were 166 
administered intrathecally (26 gauge needle) at the lumbar enlargement of mice as single bolus 167 
injections (5 μl). Cancer and sham operated mice were day 14 randomized into three treatment 168 
groups according to their 50% PWT and then treated once daily on days 15-17 after cancer cell 169 
inoculation. Cancer operated mice were administered either vehicle (n=10) or α-CGRP8-37 (5 nmol, 170 
n=10). Sham operated mice were administered vehicle (n=7). Behavioral testing was performed 60 171 
min post administration. The experimenter was blinded to both operation and treatment groups.  172 
 173 
2.7. Immunohistochemistry 174 
IHC in femurs: Mouse femurs inoculated with cancer cells or media were isolated on days 20-175 
22 after surgery. Femurs were cut open at the distal end, fixed in 4% PFA for 48 hours at RT, and then 176 
stored in saline at 4°C. They were gently decalcified in 10% EDTA adjusted to pH 7.3 for 2 weeks at 177 
4°C, and cryoprotected in 30% sucrose in 0.1 M PBS prior to embedding in O.C.T. Compound (VWR, 178 
Leicestershire, UK). The femurs were serially sectioned along the longitudinal axis into 30 μm 179 
sections on a cryostat (Leica CM 3050 S Cryostat) and thaw mounted onto gelatine coated 180 
microscope slides. Adjacent sections were subjected to either hematoxylin & eosin (H&E) staining or 181 
fluorescent immunohistochemistry. Sections for H&E were stained following standard procedures, 182 
dried 1 hour at 60°C, washed 3 times with xylene and mounted with DPX (Sigma-Aldrich, Dorset, UK) 183 
mounting medium for imaging. Fluorescent immunohistochemistry was performed as previously 184 
described [26]. Sections were blocked for 1 hour in 1% bovine serum albumin (BSA, Sigma-Aldrich) in 185 
0.3% Triton X-100 (Sigma-Aldrich) in 0.1 M phosphate buffered saline (T-PBS), and incubated 186 
overnight at RT with sheep anti-CGRP (BML-CA1137, 1:800, Enzo Life Sciences, Exeter, UK), followed 187 
by 2 hours incubation with donkey anti-sheep Cy™3-conjugated AffiniPure F(ab')2 fragment (713-188 
166-147, 1:1000, Jackson ImmunoResearch Laboratories, Suffolk, UK). Sections were then mounted 189 
with Vectashield mounting medium containing DAPI (Vector Laboratories, Peterborough, UK). 190 
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Peptidergic sensory fibres in the femur were visualized by confocal microscopy and images acquired 191 
with Zeiss Axio Imager Z2 and LSM 710 system. H&E stained sections were used to microscopically 192 
identify bone tissue, bone marrow and cancer cells. Confocal images of adjacent immunofluorescent 193 
femur sections were acquired as a Z-stack using a 40x objective and the final image projected from 194 
80 optical sections at 0.25 μm intervals. A total of 4 sham operated mice and 5 cancer-bearing mice 195 
were qualitatively inspected.  196 
IHC in dorsal root ganglia: Ipsilateral and contralateral dorsal root ganglia (DRG) L4 were 197 
isolated on days 20-22 after cancer cell or sham inoculation. DRG were fixed in 4% paraformaldehyde 198 
(PFA) in PBS overnight at 4°C and transferred to 30% sucrose in 0.1 M PBS for cryo-protection (72 199 
hours, 4°C) prior to embedding in O.C.T. Compound. DRG were cut in 15 μm sections on a cryostat 200 
and thaw mounted onto SuperFrost plus microscope slides (Menzel Glazer, VWR, Leicestershire, UK). 201 
DRG sections were blocked 1 hour in 1% BSA in T-PBS supplemented with 0.1% sodium azide (Sigma-202 
Aldrich, Dorset, UK), and incubated overnight at RT with sheep anti-CGRP (1:800), followed by 2 203 
hours incubation at room temperature with donkey anti-sheep Cy™3-conjugated AffiniPure F(ab')2 204 
fragment (1:1000). After a rinse in PBS sections were incubated 4 hours at RT with mouse anti-βIII 205 
tubulin (G172A, 1:1000, Promega, Southampton, UK), followed by 1 hour incubation at RT with goat 206 
anti-mouse Alexa Fluor 488 (A-11001, 1:1000, Molecular Probes, Life Technologies , Paisley, UK). 207 
After a final rinse in PBS sections were mounted with Vectashield mounting medium with DAPI. 208 
CGRP-immunoreactivity (IR) and βIII tubulin-IR were visualized with a Zeiss Axioplan 2 fluorescent 209 
microscope. Images were acquired with AxioVision (v. 4.8.3.0, Carl Zeiss MicroImaging GmbH, Jena, 210 
Germany). All neuronal cell bodies in the DRGs were identified as positive for βIII tubulin. The 211 
intensity of CGRP-IR was measured by densitometry and the areas of the individual cell bodies were 212 
determined using ImageJ (version 1.46r, Wayne Rasband, National Institutes of Health, Bethesda, 213 
MD). A single cell body was considered high in CGRP-IR when the mean grey level intensity was 50% 214 
higher than the average mean grey level calculated for all cells bodies in the section subjected to 215 
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analysis. The percentage of cell bodies expressing high level of CGRP-IR was calculated from the total 216 
cell numbers in each section. Three sections were analyzed per animal, and a total of 3 sham 217 
operated mice and 4 cancer-bearing mice included in the statistical analysis. 218 
IHC in dorsal horn of the spinal cord: Spinal cords from vehicle treated mice were isolated 19 219 
days after cancer cell or sham inoculation. Mice were deeply anaesthetized with pentobarbital (12.5 220 
mg/mouse, i.p., Euthal, Merial) and euthanized by intracardial perfusion with ice cold saline followed 221 
by 4% PFA in PBS. Lumbar spinal cords were isolated, post fixed 4 hours in 4% PFA at 4°C, and 222 
transferred to 30% sucrose in PBS for cryo-protection (72 hours, 4°C) prior to embedding in O.C.T. 223 
Compound. Spinal cords were cut in 20-30 μm transverse sections on a cryostat and either thaw 224 
mounted onto SuperFrost microscope slides or stained as free floating sections. Spinal cord sections 225 
were blocked for 1 hour in 1% BSA in 0.1-0.3% T-PBS prior to overnight incubation at RT with primary 226 
antibody. Primary antibodies included sheep anti-CGRP (1:1000), mouse anti-GFAP (glial fibrillary 227 
acidic protein, G6171, 1:500, Sigma-Aldrich, Dorset, UK), mouse anti-NeuN (neuronal nuclei clone 228 
A60, MAB377, 1:500, Merch Millipore, Hertfordshire, UK), rabbit anti-CLR (calcitonin receptor-like 229 
receptor, C3866, 1:100, Sigma-Aldrich) and rabbit anti-RAMP1 (receptor activity-modifying protein 1, 230 
SC11379, 1:50, Santa Cruz Biotechnology, Heidelberg, Germany). Following a rinse in PBS sections 231 
were incubated 2 hours at RT with appropriate secondary antibodies, including donkey anti-sheep 232 
Cy3-conjugated AffiniPure F(ab')2 fragment (1:800), goat anti-rabbit Alexa Fluor 488 (A-11008, 1:100, 233 
Molecular Probes, Life Technologies, Paisley, UK), goat anti-mouse Alexa Fluor 488 (A-11001, 234 
1:1000), chicken anti-goat Alexa Flour 488 (A-21467, 1:1000) and donkey anti-rabbit Alexa Flour 546 235 
(A-10040, 1:1000). All antibodies were applied in 1% BSA in T-PBS. Sections were mounted with 236 
Vectashield mounting medium with DAPI. CGRP-IR was visualized with a Zeiss Axioplan 2 fluorescent 237 
microscope. Images were acquired with AxioVision (v. 4.8.3.0, Carl Zeiss MicroImaging GmbH, Jena, 238 
Germany). CGRP-IR was quantified by densitometry; a total of nine squares measuring an area of 15 239 
µm x 15 µm were placed in the lateral, central and medial part of the superficial dorsal horn. No 240 
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differences were found between the three parts, why the mean grey level were averaged for all nine 241 
squares and subjected to analysis.  242 
Co-localization of CGRP receptor components CLR and RAMP1 in neurons and astrocytes was 243 
determined in the ipsilateral dorsal horn of the spinal cord. Images were acquired with a confocal 244 
microscope (Zeiss Axio Imager Z2 and LSM 710 system) using a 20x objective. Analysis was performed 245 
in ImageJ (version 1.41, Wayne Rasband, National Institutes of Health, Bethesda, MD) on a 246 
predefined area of 400 μm x 600 μm covering laminae I-IV. Neurons were determined as NeuN 247 
positive (NeuN+) cells; this stain is seen primarily in the nucleus with a lighter stain in cytoplasm. 248 
Astrocytes were determined as GFAP positive (GFAP+) cells. Co-localization was quantified by count 249 
of cells positive for NeuN or GFAP alone or cells with co-localization of either CLR or RAMP1, 250 
respectively. Identification of lamina was facilitated by DAPI staining of cell nuclei, and only cells with 251 
clearly observable nuclei in the focal plane were included in the analysis. For all analyses three 252 
sections were analyzed per animal, and a total of 4 sham operated mice and 5 cancer-bearing mice 253 
included in the statistical analysis.  254 
 255 
2.8. Culture of adult spinal cord astrocytes 256 
Primary cultures of astrocytes were prepared from spinal cords of adult female Sprague-257 
Dawley rats (≈ 150 g, Harlan, Oxfordshire, UK) according to a protocol described by Codeluppi et. al. 258 
[9]. Briefly rats were anaesthetized deeply with pentobarbital and euthanized by decapitation. The 259 
spinal cord was quickly harvested by hydroextrusion with ice cold 0.1 M PBS and placed in complete 260 
medium consisting of basal Astrocyte Medium supplemented with 2% fetal bovine serum, 50 U/ml 261 
penicillin, 50 μg/ml streptomycin and Astrocyte Growth Supplement (all reagents from ScienCell 262 
Research Laboratories, Carlsbad, CA). Meninges and capillaries were removed and the spinal cord 263 
chopped into small pieces using a razor blade. The spinal cord pieces were incubated for 10 min at 264 
37°C in 0.25% w/v trypsin-EDTA (Life Technologies, Paisley, UK), and following a wash in complete 265 
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medium they were thoroughly triturated in complete medium. To remove fibroblasts, cell 266 
suspensions were pre-adhered for 30 min at 37°C in an uncoated cell culture flask (75 cm2, Nunc™). 267 
The supernatant was then collected and transferred into a poly-D lysine (10 μg/ml) coated cell 268 
culture flask. Complete medium was replaced on day 4, 7 and 10. The astrocytes were allowed to 269 
grow to almost full confluence. On days 11 and 12 any remaining microglia were removed by a 10 270 
min shake at 1000 rpm followed by an immediate replacement of complete medium. The following 271 
day astrocytes were washed with 0.1 M PBS, harvested with 0.25% trypsin-EDTA in 0.1 M PBS, 272 
centrifuged at 1000g and re-suspended in complete culture medium. Astrocyte numbers were 273 
counted, the astrocytes diluted to the desired concentration in complete medium, and then plated 274 
into 24 or 96 well plates depending on the specific assay. 275 
  276 
2.9. Assay for cyclic AMP 277 
Astrocytes were cultured in 96 well plates coated with poly-D lysine (10 μg/ml) at a density of 278 
40,000 cells/well. After 48 hours of incubation the culture medium was renewed and the astrocytes 279 
were incubated in fresh media for 3 hours prior to experimentation. All astrocytes were pre-treated 280 
for 30 min with 3-isobutyl-1-methylxanthine (IBMX, 100 μM, Tocris Bioscience, Abingdon, UK) to 281 
prevent the degradation of cAMP, followed by 15 minutes pre-treatment with either vehicle 282 
(complete astrocyte medium) or the CGRP peptide antagonist CGRP8-37 (1-10 μM, Tocris 283 
Bioscience).Then astrocytes were incubated for 15 minutes with vehicle, forskolin (1 μM, Tocris 284 
Bioscience), CGRP (1 – 1000 nM, Alpha Diagnostic Intl Inc., Nottingham, UK), or CGRP8-37 (10 μM). 285 
Each treatment was performed in triplicate. All drugs were dissolved in astrocyte complete media 286 
from stock solutions and supplemented with forskolin (1 μM) to activate adenylate cyclase and 287 
induce formation of detectable levels of cAMP. At the end of treatments media were removed, lysis 288 
buffer (100 μL) was added to each well and incubated for 30 minutes at 37°C. cAMP was measured in 289 
lysates by competitive immunoassay (cAMP-Screen® ELISA System, Applied Biosystems, Bedford, 290 
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MA). A standard curve (0.006 – 6,000 pmol) and unknown samples were run in triplicate according to 291 
the manufacture’s instruction. Bioluminescence was measured with a luminometer (SpectraMax 292 
340PC384, Molecular Devises LLC, Berkshire, UK), and cAMP concentrations in unknown samples 293 
were calculated from the standard curve using linear regression.  294 
 295 
2.10. Assay for ATP release 296 
Astrocytes were cultured in 24 well plates coated with poly-D lysine (10 μg/ml) at a density of 297 
25,000 cells/well. After 48 hours of incubation the culture medium was renewed and the astrocytes 298 
incubated for 3 hours in fresh media prior to experimentation. Astrocytes were pre-treated for 15 299 
minutes with vehicle or the CGRP peptide antagonist CGRP8-37 (10 μM, Tocris Bioscience, Abingdon, 300 
UK). Then astrocytes were incubated for 15 min with CGRP (1000 nM, Alpha Diagnostic Intl Inc., 301 
Nottingham, UK), glutamate (1 mM, Sigma-Aldrich, Dorset, UK), or stimulated mechanically (three 302 
careful flushes of cells). Each treatment was performed in eight wells. All drugs were dissolved in 303 
astrocyte complete media from stock solutions and supplemented with the ecto-ATPase inhibitor 304 
ARL 67156 (100 μM, Sigma-Aldrich). At the end of treatments media were removed and ATP content 305 
measured with a CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Southampton, UK). An 306 
ATP standard curve (10-4 – 10-13 M) was run in triplicate and unknown samples in duplicate according 307 
to the manufacture’s instruction. Bioluminescence was measured with a luminometer. ATP 308 
concentrations in unknown samples were calculated from the standard curve using linear regression 309 
and were normalized to vehicle.  310 
 311 
2.11. Statistical analysis 312 
Data are presented as mean ± standard error of mean (SEM). Statistical analysis was 313 
performed using GraphPad Prism (v. 5.01 for Windows, GraphPad Software Inc., La Jolla, CA). 314 
Immunohistochemical data were analyzed with either two-way or one-way analysis of variance 315 
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followed by Bonferroni or Newman-Keuls multiple comparison test, respectively. Student’s t-test was 316 
used for analysis of co-localization of CGRP receptor components in neurons and astrocytes. 317 
Extracellular CGRP release was analyzed with two-way ANOVA followed by Bonferroni’s post-test. 318 
Student’s t-test was used to compare individual fractions. Behavioral data was analyzed with two-319 
way ANOVA followed by Bonferroni’s post-test. Analysis of cAMP generation and ATP release were 320 
performed with one-way ANOVA followed by Dunnett’s multiple comparison test or Newman-Keuls 321 
multiple comparison test. For all statistical analyses, a probability value of P < 0.05 was considered 322 
signiﬁcant. 323 
 324 
3. Results 325 
3.1. Sprouting of peptidergic sensory fibers in cancer cell inoculated femurs. 326 
Osteosarcoma is an osteolytic bone cancer that induces substantial bone resorption [32], and 327 
has been associated with sprouting of peptidergic CGRP+ fibers in the C3H mouse model of cancer-328 
induced bone pain [26]. Consistently, we observed sprouting of CGRP positive fibers in cancer-329 
bearing femurs which were isolated on days 20-22 after cell inoculation (Fig. 1A-C). Femur bones of 330 
sham operated mice showed a highly linear morphology of CGRP+ positive fibers (Fig. 1A). In contrast 331 
an unorganized sprouting of CGRP+ fibers was observed in the ipsilateral femur bone of cancer-332 
bearing mice (Fig. 1B,C). 333 
 334 
3.2. CGRP-IR is increased in small diameter cell bodies in DRG, but not in the superficial dorsal horn of 335 
the spinal cord ipsilateral to cancer cell inoculated femurs. 336 
Next we evaluated whether the increase of CGRP-expressing fibers in the cancer-bearing bone 337 
was mirrored by peptide changes in the cell bodies of the sensory neurons in the DRG and/or in their 338 
central terminals in the dorsal horn of the spinal cord. 339 
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L4 DRG and superficial dorsal horn of the L4 segment of the spinal cord were selected for CGRP 340 
quantification as significant neurochemical and cellular reorganization have previously been 341 
demonstrated at this level in the osteosarcoma model of cancer-induced bone pain [18,32].  342 
As expected, CGRP was mostly expressed by small diameter cells in ipsilateral and contralateral 343 
DRG obtained from cancer and sham inoculated mice (Fig. 1D-F). However, at 20-22 days after cancer 344 
cell inoculation the percentage of ipsilateral small cell bodies (300-600 μm2) expressing high CGRP-IR 345 
was 88% higher than that in sham DRG (Fig. 1F). Overall, there was a 40% increase in the percentage 346 
of ipsilateral DRG cell bodies expressing high CGRP-IR when comparing cancer-bearing mice to sham 347 
operated mice (Fig. 1G).  348 
The increased numbers of cells expressing CGRP in L4 DRG was not matched by changes in 349 
CGRP-IR expression at the central terminals of primary afferent fibers in either ipsilateral or 350 
contralateral dorsal horn of cancer-bearing mice compared to sham operated mice (Fig. 1H-J). 351 
Previously, using histochemical techniques, CGRP content in the ipsilateral superficial dorsal horn has 352 
been reported as unaltered after induction of cancer-induced bone pain [19]. Therefore, it is 353 
conceivable that our method is not sensitive enough to detect an increase in an already CGRP rich 354 
area.  355 
 356 
3.3. Extracellular CGRP levels are higher in the dorsal horns of mice with cancer-induced bone pain.  357 
As the aim of this study was to evaluate whether central changes in the CGRP system play a 358 
role in the development of pain-related behaviors in cancer-induced bone pain, we tested the 359 
alternate hypothesis that activity-induced release of CGRP from primary afferent fibers in the dorsal 360 
horn might be altered as a result of the increased CGRP content in the ipsilateral DRG cell bodies. 361 
Only cancer-bearing mice with a limb use score ≤ 3 were included in the experiment (average score 362 
1.8±0.7 compared to 3.9±0.4 for sham operated mice, P < 0.001, data not shown).  363 
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Basal and activity-evoked release of CGRP in the dorsal horn was measured using the ex-vivo 364 
dorsal horn slice preparation with lumbar dorsal roots attached. Overall, significantly higher levels of 365 
extracellular CGRP were measured in slices obtained from cancer-bearing mice compared to sham 366 
operated mice (F[1, 45] = 16.42, P > 0.001, two-way ANOVA). Electrical stimulation of the dorsal 367 
roots using parameters that mimic transmission of noxious stimuli resulted in a significant increase of 368 
CGRP content in dorsal horn superfusates of cancer-bearing compared to sham operated mice (Fig. 369 
2A). However, the 65% increase over basal level in cancer-bearing mice was not significantly different 370 
from the 100% increase over basal level measured in slices from sham operated mice (Fig. 2A). 371 
Further analysis revealed that basal and recovery outflow levels were significantly higher in slices 372 
from cancer-bearing mice compared to sham operated mice (Fig. 2A).  373 
These data indicate that an increased pool of primary afferent fiber-derived CGRP is available 374 
in the spinal cord dorsal horn of cancer-bearing mice under both basal and noxious-like condition.  375 
 376 
3.4. Intrathecal administration of CGRP8-37 attenuates mechanical allodynia in mice with cancer-377 
induced bone pain. 378 
To investigate the biological relevance of the increased level of primary afferent fiber-derived 379 
CGRP in the dorsal horn of cancer-bearing mice, we tested the analgesic potential of a CGRP peptide 380 
antagonist delivered intrathecally at the lumbar spinal cord level.  381 
Significant hypersensitivity to applied mechanical stimulation was detected in hindpaws 382 
ipsilateral to the cancer cell inoculated femurs on days 9, 11 and 14-17 after inoculation (Fig 2B,C). 383 
Also, a shift was seen in the body weight load on the cancer-bearing hind leg resulting in a 384 
significantly decreased weight bearing ratio starting day 14 in cancer-bearing mice as compared to 385 
sham operated mice (Fig 2D,E). 386 
Injections of α-CGRP8-37 on days 16 and 17 significantly attenuated mechanical allodynia 60 387 
min after each injection producing a 44% reversal of allodynia as compared to vehicle treated cancer-388 
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bearing mice (Fig. 2C). Injection of α-CGRP8-37 did not significantly attenuate allodynia on day 15 389 
after cancer cell inoculation, although there was a trend towards an increase in the 50% PWT. A 390 
similar effect of α-CGRP8-37 was observed in the weight bearing set up with a significant increase in 391 
the weight bearing ratio between inoculated and non-inoculated hind leg on days 16 and 17 as 392 
compared to vehicle treated cancer-bearing mice (Fig. 2E). Previous experiments in our laboratory 393 
have demonstrated that intrathecal injections of α-CGRP8-37 have no effect on pain-related 394 
behaviors in sham operated mice (data not shown), thus this group was omitted.  395 
These data suggest that an increased primary afferent fiber input to the dorsal horn results in 396 
release of CGRP which may maintain osteosarcoma-induced mechanical allodynia.  397 
 398 
3.5. Increased expression of CGRP receptor components CLR and RAMP1 in neurons and astrocytes in 399 
the dorsal horn of cancer cell inoculated mice. 400 
In order to provide a site of action for extracellular CGRP, we quantified the cellular expression 401 
of CGRP receptor components in the dorsal horn of cancer-bearing and sham operated mice. As 402 
expected, the induction of cancer in the bone was associated with the presence of reactive 403 
astrocytes (GFAP+ cells) in the ipsilateral dorsal horn of the spinal cord. The expression of the two 404 
CGRP receptor components, calcitonin receptor-like receptor (CLR) and receptor activity-modifying 405 
protein 1 (RAMP1), was observed in both neurons (Fig. 3A,B) and astrocytes (Fig. 4A,B). 406 
A significant increase was observed in the numbers of neurons co-expressing either CLR or 407 
RAMP1 in cancer-bearing mice compared to sham operated mice (Fig 3C,D). Specifically, the 408 
expression of both receptor components in neurons nearly doubled in the superficial laminae (I-IV) of 409 
cancer-bearing mice compared to sham operated mice. 410 
Alongside neurons, a higher number of GFAP+ cells (astrocytes) were found to express CLR and 411 
RAMP1 in cancer-bearing mice compared to sham operated mice (Fig. 4C,D). Yet, as numbers of 412 
GFAP+ cells in the dorsal horn of cancer-bearing mice was increased by two-fold the percentage of 413 
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astrocytes expressing the CGRP receptor components over the total GFAP+ cell population was 414 
similar in the dorsal horn of sham and cancer inoculated mice (Fig. 4C,D). Notably, the increased 415 
numbers of GFAP+ cells does not reflect an increase of astrocyte numbers, but rather their 416 
transformation into a reactive state [36]. Thus, we suggest that reactive astrocytes carry CGRP 417 
receptors which could respond to the increased level of extracellular CGRP in the dorsal horn of 418 
cancer-bearing mice. 419 
 420 
3.6. Cultured adult rat spinal cord astrocytes respond functionally to treatment with CGRP. 421 
Whether CGRP receptors in astrocytes respond functionally to CGRP was investigated by 422 
measuring the generation of cAMP in primary cultures of astrocytes isolated from adult rat spinal 423 
cords.  424 
CGRP application to cultured astrocytes resulted in a concentration dependent increase in cAMP 425 
generation, with a significant increase at 100 and 1000 nM compared to vehicle (Fig. 5A). Pre-426 
treatment with the CGRP peptide antagonist CGRP8-37 (1-10 μM,) significantly attenuated the 427 
generation of cAMP in response to 100 nM CGRP (Fig. 5A). CGRP8-37 itself had no effect on cAMP 428 
generation (data not shown). Furthermore, CGRP stimulation (1 μM) resulted in a two-fold increase 429 
in ATP release, which could be attenuated by CGRP8-37 (Fig. 5B).  430 
Together, these data indicate the expression of functional CGRP receptors on spinal cord 431 
astrocytes which could respond to the increased extracellular CGRP in the dorsal horn of cancer 432 
bearing mice.  433 
 434 
4. Discussion 435 
We provide evidence for increased levels of extracellular CGRP in the dorsal horn of the 436 
lumbar spinal cord in mice with cancer-induced bone pain. Cancer-bearing mice displayed 437 
spontaneous pain-like behavior as well as referred allodynia. Specifically, we observed that in dorsal 438 
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horn superfusates obtained from cancer-bearing mice overall CGRP levels were significantly higher 439 
than in slices from sham operated mice, and accordingly activity-evoked release of this peptide 440 
reached values 58% higher than in sham operated mice. However, the primary afferent fiber activity-441 
evoked release of CGRP over basal levels was not different in cancer-bearing mice and sham 442 
operated mice, respectively. Therefore, we conclude, as a result of basal levels of CGRP being higher 443 
under cancer-induced bone pain conditions, that overall CGRP extracellular levels are increased in 444 
the dorsal horn.  445 
The increase of extracellular CGRP in the spinal cord was mirrored by significant sprouting of 446 
CGRP-expressing fibers innervating the metastatic site. The original sources of peripheral and central 447 
CGRP pools are the cell bodies of sensory neurons in the lumbar DRG, and we confirmed that larger 448 
numbers of DRG (L4) neuronal cell bodies expressed high CGRP content ipsilateral to the cancer-449 
bearing bone. 450 
Current evidence suggests that NGF is required for sensory fiber sprouting in skeletal bone 451 
affected by cancer, and blockage of peripheral NGF impairs the occurrence of cancer-induced bone 452 
pain [21,26,35]. Furthermore, peptidergic fibers express receptors for hematopoietic growth factors 453 
and respond to granulocyte-macrophage colony-stimulating factors (G-CSF and GM-CSF) by releasing 454 
CGRP in the skin adjacent to tumor growth [33]. The observation that neutralization of G-CSF and 455 
GM-CSF receptors in the vicinity of the tumor attenuated cancer-induced pain related behaviors and 456 
tumor growth, point towards a critical role played by peripheral sensitization of neurons interacting 457 
with trophic factors released by tumor and stromal cells [34]. Indeed, tumor cells can deregulate the 458 
expression of a unique signature of microRNAs in sensory neurons thereby modulating the 459 
expression of pain-related genes which are functionally important in tumor-induced nociceptive 460 
hypersensitivity in vivo [1].  461 
Our study adds further details to these peripheral mechanisms, providing evidence that CGRP 462 
up-regulation in the DRG is associated with increased availability of this peptide centrally at the first 463 
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sensory synapse in the dorsal horn. Here extracellular CGRP can act on CGRP receptors expressed in 464 
dorsal horn neurons. We found that CGRP receptor components were present in higher numbers 465 
than under normal conditions, and therefore, CGRP may act by enhancing neuronal activation driven 466 
by glutamate [24]. In agreement, we found that a CGRP receptor antagonist (α-CGRP8-37) injected at 467 
the lumbar spinal cord level attenuated bone cancer-induced allodynia.  468 
Our data indicates that an increased primary afferent input into the dorsal horn is responsible 469 
for allodynia in cancer-induced bone pain. Glutamate drives neuronal activation at the spinal level in 470 
cancer-induced bone pain through activation of NMDA receptors [17,40]; an effect that is 471 
potentiated by CGRP [24]. Thus, cancer-induced bone pain induces a state of central sensitization in 472 
which changes in the spinal cord facilitate an increased transmission of nociceptive information. 473 
Indeed, the ratio of wide dynamic range (WDR) neurons to nociceptive specific (NS) neurons shifts to 474 
47%:53% from 26%:74% which is observed under normal conditions [38]. Moreover, this increase in 475 
WDR neurons over NS neurons is accompanied by increased hyperexcitability of the WDR neurons 476 
[12,22]. The observation that intrathecal administration of CGRP increase the activity of WDR 477 
neurons further supports a role CGRP and CGRP receptors in driving of central sensitization in cancer-478 
induced bone pain [41]. 479 
Furthermore, our evidence suggests that neurons are not the only cells mediating the effect of 480 
CGRP. Specifically, we observed that reactive astrocytes in the dorsal horn ipsilateral to the cancer-481 
bearing bone expressed CGRP receptors (CLR/RAMP1). Reactive astrocytes are a typical feature in 482 
models of cancer-induced bone pain [18,19], and they may increase extracellular glutamate levels as 483 
reactive astrocytes usually decrease the expression of glutamate-uptake transporters [16]. Our data 484 
indicate that the activation of CGRP receptors results in cAMP formation and release of ATP from 485 
astrocytes, and such mechanisms within the astrocytic network are able to enhance nociceptive 486 
signaling.  487 
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The neuromodulatory role of ATP can be mediated by purinergic ligand gated ion channels, 488 
P2X2/3 and P2X3 receptors, expressed on the central terminals of primary afferent neurons, which 489 
transiently enhance the release of presynaptic glutamate [28,39]. Evidence suggests that a rapid non-490 
vesicular release of glutamate can occur in response to P2X7 receptor activation [13], but also in a 491 
P2X7 receptor independent manner involving activation of astrocytic P2Y1 receptors [15,42]. 492 
Although an astrocytic expression of P2X7 receptors has been questioned [2,7], according to current 493 
views these receptors become detectable due to up-regulation in pathological states [10]. Thus, in 494 
the spinal cord the increased release of sensory neuron-derived CGRP may activate CGRP receptors 495 
expressed on astrocytes leading to release of ATP which can activate both astrocytes (P2X7R) and 496 
neurons (P2X3R), thereby facilitating nociception in cancer-induced bone pain. In support of this 497 
possibility experimental evidence has demonstrated that spinal application of a P2X7 receptor 498 
antagonist attenuated dorsal horn evoked neuronal responses to high-intensity mechanical and 499 
thermal stimulation in cancer-bearing mice [14]. Also, intrathecal delivery of a P2X3 receptor 500 
antagonist attenuated cancer induced bone pain [23]. Together, these series of evidence indicate 501 
that P2X3 and P2X7 receptors may be involved in the central mechanisms driving cancer-induced 502 
bone pain, and the findings contribute to the understanding of the intercellular communication 503 
between astrocytes and neurons which may hold new therapeutic targets for cancer-induced bone 504 
pain. 505 
In conclusion, this study demonstrates that the peripheral increase in CGRP content observed 506 
in cancer-induced bone pain is mirrored by a central increase in the extracellular levels of CGRP. This 507 
increase in centrally available CGRP may facilitate glutamate-driven neuronal nociceptive signaling, 508 
but may also act on astrocytic CGRP receptors and lead to release of ATP. 509 
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Figure Legends 640 
Fig. 1. Sprouting of peptidergic sensory fibers and expression of calcitonin gene-related peptide- 641 
immunoreactivity (CGRP-IR) in dorsal root ganglion (DRG) cell bodies and superficial dorsal horns of 642 
the spinal cord. (A-C) Representative confocal images of bone sections demonstrating CGRP+ fiber 643 
innervation in sham operated and cancer-bearing mice 20-22 days post osteosarcoma cell 644 
inoculation. Sprouting of peptidergic sensory nerve fibers is evident in bone sections of cancer-645 
bearing animals, while linear sensory fibers are observed in sham mice. DAPI staining visualizes cell 646 
nuclei. (D, E) Representative images of CGRP-IR and beta-III tubulin-IR in L4 DRG isolated 20-22 days 647 
post osteosarcoma cell inoculation. (F) Quantification of DRG cell bodies which express high CGRP-IR 648 
and distribution by cell size (μm2). (G) Quantification of the total percentage of DRG cell bodies which 649 
express high CGRP-IR. (H, I) Representative images of intracellular CGRP-IR in L4 spinal cord dorsal 650 
horns obtained 19 days post osteosarcoma cell inoculation or sham operation. (J) Quantification of 651 
CGRP-IR in the superficial dorsal horn. (F) **P < 0.01 and +P < 0.05 compared to small size cell bodies 652 
(300-600 μm2) ipsilateral in sham operated mice and contralateral in cancer-bearing mice, 653 
respectively. (G) *P < 0.05 compared to ipsilateral site in sham operated mice and contralateral site 654 
in cancer-bearing mice, n = 3-4 in each group, 3 sections per animal. (J) n = 4-5 in each group, 3 655 
sections per animal. All scale bars, 100 μm. 656 
 657 
Fig. 2. Higher extracellular levels of CGRP in the dorsal horn of cancer cell inoculated mice and 658 
attenuation of pain-related behaviors by intrathecal delivery of a CGRP antagonist. (A) Extracellular 659 
CGRP content in dorsal horn superfusates under basal conditions, after noxious-like electrical 660 
stimulation of the attached dorsal roots (C-fiber strength, 20V, 0.5ms and 10Hz), and during recovery 661 
to basal levels. Lumbar spinal cords were obtained from sham operated and cancer-bearing mice day 662 
20-22 post osteosarcoma cell inoculation. (B, D) Cancer-bearing mice demonstrate mechanical 663 
hypersensitivity in the ipsilateral hind paw and reduced weight bearing of the cancer-bearing hind 664 
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limb compared to sham operated mice. (C, E) On day 16 and 17 paw withdrawal thresholds (PWT) 665 
and weight bearing ratios were increased 60 min after intrathecal (i.t.) injections of the CGRP peptide 666 
antagonist α-CGRP8-37 (5 nmol/5 μl) compared to vehicle treated cancer-bearing mice. (B, D) **P < 667 
0.01 and ***P < 0.001 compared to sham operated mice, n = 7-20 in each group. (C, E) *P < 0.05 and 668 
**P < 0.01 compared to vehicle treated cancer-bearing mice, n = 7-10 in each group. BL, baseline. 669 
 670 
Fig.3. Increased expression of calcitonin gene-related peptide receptor components CLR and RAMP1 671 
in dorsal horn neurons ipsilateral to the cancer-bearing bone. (A, B) Representative confocal images 672 
demonstrating co-localization of neurons (NeuN+) and receptor components CLR and RAMP1 in L4 673 
ipsilateral dorsal horn of sham operated and cancer-bearing mice day 19 post osteosarcoma cell 674 
inoculation. (C, D) Quantification of the numbers of dorsal horn neurons expressing CLR or RAMP1 in 675 
cancer-bearing and sham operated mice. *P < 0.05 and ***P < 0.001, n = 4-5 in each group, 3 676 
sections per animal. Scale bar, 100 μm; scale bar insert, 10 μm. NeuN, neuronal nuclei; CLR, 677 
calcitonin-like receptor; RAMP1, receptor activity modifying protein 1. 678 
 679 
Fig. 4. Increased expression of calcitonin gene-related peptide receptor components CLR and RAMP1 680 
in astrocytes in the dorsal horn ipsilateral to the cancer-bearing bone. (A, B) Representative images 681 
demonstrating co-localization of astrocytes positive for GFAP-IR (GFAP+) and receptor components 682 
CLR and RAMP1 in L4 ipsilateral dorsal horn of sham operated and cancer-bearing mice. (C, D) 683 
Quantification of GFAP+ astrocytes and CLR or RAMP1 expression in cancer-bearing mice compared to 684 
sham operated mice. No difference was found in the expression of CGRP receptor components per 685 
astrocyte in spinal cords from cancer-bearing mice compared to sham operated mice. *P < 0.05 and 686 
**P < 0.01, n = 4-5 in each group, 3 sections per animal. Scale bar, 100 μm; scale bar insert, 10 μm. 687 
GFAP, glial fibrillary acidic protein; CLR, calcitonin-like receptor; RAMP1, receptor activity modifying 688 
protein 1. 689 
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 690 
Fig. 5. Cultured adult rat spinal cord astrocytes respond functionally to calcitonin gene-related 691 
peptide application. (A) cAMP generation was measured 15 min after stimulation with vehicle, 692 
forskolin or CGRP. Pre-treatment with either vehicle or CGRP8-37 was started 15 min before CGRP 693 
application. (B) ATP release was determined 15 min after application of vehicle, CGRP, glutamate or 694 
mechanical stimulation (3 careful flushes of cells with pipette). Vehicle or CGRP8-37 pre-treatment 695 
was started 15 min before CGRP application. (A) **P < 0.05 and ***P < 0.001 compared to 696 
stimulation with forskolin 1 μM. ##P < 0.01 and ###P < 0.001 compared to CGRP (100 nM) 697 
supplemented with forskolin (1 μM), n = 3 stimulations per condition, representative of one 698 
experiment. (B) *P < 0.05, **P < 0.01 and ***P < 0.001 compared to vehicle, n = 6-8 stimulations per 699 
condition, data pooled from two separate experiments. 700 
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Summary 1 
Increased central levels of extracellular CGRP and CGRP receptors expressed on neurons and 2 
astrocytes may facilitate nociception in cancer-induced bone pain. 3 
Summary
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